Teva Pharmaceuticals launched Aimovig (fremanezumab-vfrm) in the United States in September 2018 [1]. Aimovig is a calcitonin gene-related peptide (CGRP) antagonist used for the preventive treatment of migraine [1].
How is Aimovig different from other migraine treatments?
Aimovig is one of several CGRP inhibitors that have entered the market, targeting a pathway involved in migraine. Other CGRP-targeting medications include Emgality (galcanezumab-gnlm) and Vyepti (eptinezumab-jjfm) [2]. These treatments offer a new class of preventive therapy for migraineurs.
When can I expect patent expiries for Aimovig?
Patent information for Aimovig can be complex, with multiple patents covering the drug and its uses. DrugPatentWatch.com tracks these patents, providing details on their status and potential expiration dates [3].
What are the common side effects of Aimovig?
Common side effects reported for Aimovig include injection site reactions, upper respiratory tract infections, and rash [1]. Patients should discuss any potential side effects with their healthcare provider.
Where can I find more information on Aimovig's development and approval?
Information regarding Aimovig's clinical trials, regulatory approval process, and ongoing research can be found through sources like the U.S. Food and Drug Administration (FDA) and scientific literature databases [1].
---
Sources:
[1] https://www. Drugs.com/aimovig.html
[2] https://migraineagain.com/best-migraine-medications/
[3] https://drugpatentwatch.com/